Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1999 Nov;58(Suppl 1):I114–I120. doi: 10.1136/ard.58.2008.i114

Anti-TNF antibody treatment of Crohn's disease

S J H van Deventer
PMCID: PMC1766571  PMID: 10577987

Full Text

The Full Text of this article is available as a PDF (88.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bauditz J., Haemling J., Ortner M., Lochs H., Raedler A., Schreiber S. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut. 1997 Apr;40(4):470–474. doi: 10.1136/gut.40.4.470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bauditz J., Rückert Y., Raedler A., Nikolaus S., Lochs H., Schreiber S. Tumour necrosis factor inhibition by oxpentifylline and intestinal inflammation in Crohn's disease. Lancet. 1995 Jun 3;345(8962):1445–1445. doi: 10.1016/s0140-6736(95)92635-6. [DOI] [PubMed] [Google Scholar]
  3. Black R. A., Durie F. H., Otten-Evans C., Miller R., Slack J. L., Lynch D. H., Castner B., Mohler K. M., Gerhart M., Johnson R. S. Relaxed specificity of matrix metalloproteinases (MMPS) and TIMP insensitivity of tumor necrosis factor-alpha (TNF-alpha) production suggest the major TNF-alpha converting enzyme is not an MMP. Biochem Biophys Res Commun. 1996 Aug 14;225(2):400–405. doi: 10.1006/bbrc.1996.1186. [DOI] [PubMed] [Google Scholar]
  4. Black R. A., Rauch C. T., Kozlosky C. J., Peschon J. J., Slack J. L., Wolfson M. F., Castner B. J., Stocking K. L., Reddy P., Srinivasan S. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997 Feb 20;385(6618):729–733. doi: 10.1038/385729a0. [DOI] [PubMed] [Google Scholar]
  5. Boirivant M., Marini M., Di Felice G., Pronio A. M., Montesani C., Tersigni R., Strober W. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology. 1999 Mar;116(3):557–565. doi: 10.1016/s0016-5085(99)70177-0. [DOI] [PubMed] [Google Scholar]
  6. Breese E. J., Michie C. A., Nicholls S. W., Murch S. H., Williams C. B., Domizio P., Walker-Smith J. A., MacDonald T. T. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology. 1994 Jun;106(6):1455–1466. doi: 10.1016/0016-5085(94)90398-0. [DOI] [PubMed] [Google Scholar]
  7. Breese E., MacDonald T. T. TNF alpha secreting cells in normal and diseased human intestine. Adv Exp Med Biol. 1995;371B:821–824. [PubMed] [Google Scholar]
  8. Bregenholt S., Claesson M. H. Increased intracellular Th1 cytokines in scid mice with inflammatory bowel disease. Eur J Immunol. 1998 Jan;28(1):379–389. doi: 10.1002/(SICI)1521-4141(199801)28:01<379::AID-IMMU379>3.0.CO;2-X. [DOI] [PubMed] [Google Scholar]
  9. Brynskov J., Freund L., Rasmussen S. N., Lauritsen K., de Muckadell O. S., Williams N., MacDonald A. S., Tanton R., Molina F., Campanini M. C. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med. 1989 Sep 28;321(13):845–850. doi: 10.1056/NEJM198909283211301. [DOI] [PubMed] [Google Scholar]
  10. Cammà C., Giunta M., Rosselli M., Cottone M. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology. 1997 Nov;113(5):1465–1473. doi: 10.1053/gast.1997.v113.pm9352848. [DOI] [PubMed] [Google Scholar]
  11. Carp J. M., Onuma E., Das K., Gottlieb A. B. Intravenous cyclosporine therapy in the treatment of pyoderma gangrenosum secondary to Crohn's disease. Cutis. 1997 Sep;60(3):135–138. [PubMed] [Google Scholar]
  12. Cellier C., De Beenhouwer H., Berger A., Penna C., Carbonnel F., Parc R., Cugnenc P. H., Le Quintrec Y., Gendre J. P., Barbier J. P. Mycobacterium paratuberculosis and Mycobacterium avium subsp. silvaticum DNA cannot be detected by PCR in Crohn's disease tissue. Gastroenterol Clin Biol. 1998 Aug-Sep;22(8-9):675–678. [PubMed] [Google Scholar]
  13. Chadwick N., Bruce I. J., Schepelmann S., Pounder R. E., Wakefield A. J. Measles virus RNA is not detected in inflammatory bowel disease using hybrid capture and reverse transcription followed by the polymerase chain reaction. J Med Virol. 1998 Aug;55(4):305–311. [PubMed] [Google Scholar]
  14. Chiba M., Fukushima T., Horie Y., Iizuka M., Masamune O. No Mycobacterium paratuberculosis detected in intestinal tissue, including Peyer's patches and lymph follicles, of Crohn's disease. J Gastroenterol. 1998 Aug;33(4):482–487. doi: 10.1007/s005350050119. [DOI] [PubMed] [Google Scholar]
  15. Claesson M. H., Bregenholt S., Bonhagen K., Thoma S., Möller P., Grusby M. J., Leithäuser F., Nissen M. H., Reimann J. Colitis-inducing potency of CD4+ T cells in immunodeficient, adoptive hosts depends on their state of activation, IL-12 responsiveness, and CD45RB surface phenotype. J Immunol. 1999 Mar 15;162(6):3702–3710. [PubMed] [Google Scholar]
  16. Crowe P. D., Walter B. N., Mohler K. M., Otten-Evans C., Black R. A., Ware C. F. A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J Exp Med. 1995 Mar 1;181(3):1205–1210. doi: 10.1084/jem.181.3.1205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Cuvelier C. A., Quatacker J., Mielants H., De Vos M., Veys E., Roels H. M cells are damaged and increased in number in inflamed human ileal mucosa. Eur J Morphol. 1993 Mar-Jun;31(1-2):87–91. [PubMed] [Google Scholar]
  18. D'Haens G. R., Geboes K., Peeters M., Baert F., Penninckx F., Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998 Feb;114(2):262–267. doi: 10.1016/s0016-5085(98)70476-7. [DOI] [PubMed] [Google Scholar]
  19. D'haens G., Van Deventer S., Van Hogezand R., Chalmers D., Kothe C., Baert F., Braakman T., Schaible T., Geboes K., Rutgeerts P. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology. 1999 May;116(5):1029–1034. doi: 10.1016/s0016-5085(99)70005-3. [DOI] [PubMed] [Google Scholar]
  20. Derkx B., Taminiau J., Radema S., Stronkhorst A., Wortel C., Tytgat G., van Deventer S. Tumour-necrosis-factor antibody treatment in Crohn's disease. Lancet. 1993 Jul 17;342(8864):173–174. doi: 10.1016/0140-6736(93)91375-v. [DOI] [PubMed] [Google Scholar]
  21. Dumonceau J. M., Van Gossum A., Adler M., Fonteyne P. A., Van Vooren J. P., Deviere J., Portaels F. No Mycobacterium paratuberculosis found in Crohn's disease using polymerase chain reaction. Dig Dis Sci. 1996 Feb;41(2):421–426. doi: 10.1007/BF02093838. [DOI] [PubMed] [Google Scholar]
  22. Ekbom A., Daszak P., Kraaz W., Wakefield A. J. Crohn's disease after in-utero measles virus exposure. Lancet. 1996 Aug 24;348(9026):515–517. doi: 10.1016/S0140-6736(96)04429-7. [DOI] [PubMed] [Google Scholar]
  23. Elson C. O. Advances in mucosal immunity. Drugs. 1997;54 (Suppl 1):13–14. doi: 10.2165/00003495-199700541-00005. [DOI] [PubMed] [Google Scholar]
  24. Elson C. O. The basis of current and future therapy for inflammatory bowel disease. Am J Med. 1996 Jun;100(6):656–662. doi: 10.1016/s0002-9343(96)00049-6. [DOI] [PubMed] [Google Scholar]
  25. Engstrand L. Mycobacterium paratuberculosis and Crohn's disease. Scand J Infect Dis Suppl. 1995;98:27–29. [PubMed] [Google Scholar]
  26. Feagan B. G., McDonald J. W., Rochon J., Laupacis A., Fedorak R. N., Kinnear D., Saibil F., Groll A., Archambault A., Gillies R. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. N Engl J Med. 1994 Jun 30;330(26):1846–1851. doi: 10.1056/NEJM199406303302602. [DOI] [PubMed] [Google Scholar]
  27. Feagan B. G. Methotrexate treatment for Crohn's disease. Inflamm Bowel Dis. 1998 May;4(2):120–121. doi: 10.1097/00054725-199805000-00018. [DOI] [PubMed] [Google Scholar]
  28. Feagan B. G., Rochon J., Fedorak R. N., Irvine E. J., Wild G., Sutherland L., Steinhart A. H., Greenberg G. R., Gillies R., Hopkins M. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med. 1995 Feb 2;332(5):292–297. doi: 10.1056/NEJM199502023320503. [DOI] [PubMed] [Google Scholar]
  29. Feeney M., Ciegg A., Winwood P., Snook J. A case-control study of measles vaccination and inflammatory bowel disease. The East Dorset Gastroenterology Group. Lancet. 1997 Sep 13;350(9080):764–766. doi: 10.1016/s0140-6736(97)03192-9. [DOI] [PubMed] [Google Scholar]
  30. Fiocchi C. The immune system in inflammatory bowel disease. Acta Gastroenterol Belg. 1997 Apr-Jun;60(2):156–162. [PubMed] [Google Scholar]
  31. Fisher N. C., Yee L., Nightingale P., McEwan R., Gibson J. A. Measles virus serology in Crohn's disease. Gut. 1997 Jul;41(1):66–69. doi: 10.1136/gut.41.1.66. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Fowell D., Powrie F., Saoudi A., Seddon B., Heath V., Mason D. The role of subsets of CD4+ T cells in autoimmunity. Ciba Found Symp. 1995;195:173–188. doi: 10.1002/9780470514849.ch12. [DOI] [PubMed] [Google Scholar]
  33. Gearing A. J., Beckett P., Christodoulou M., Churchill M., Clements J. M., Crimmin M., Davidson A. H., Drummond A. H., Galloway W. A., Gilbert R. Matrix metalloproteinases and processing of pro-TNF-alpha. J Leukoc Biol. 1995 May;57(5):774–777. doi: 10.1002/jlb.57.5.774. [DOI] [PubMed] [Google Scholar]
  34. Green D., Kroemer G. The central executioners of apoptosis: caspases or mitochondria? Trends Cell Biol. 1998 Jul;8(7):267–271. doi: 10.1016/s0962-8924(98)01273-2. [DOI] [PubMed] [Google Scholar]
  35. Green J. T., Rhodes J., Ragunath K., Thomas G. A., Williams G. T., Mani V., Feyerabend C., Russell M. A. Clinical status of ulcerative colitis in patients who smoke. Am J Gastroenterol. 1998 Sep;93(9):1463–1467. doi: 10.1111/j.1572-0241.1998.00464.x. [DOI] [PubMed] [Google Scholar]
  36. Greenberg G. R., Feagan B. G., Martin F., Sutherland L. R., Thomson A. B., Williams C. N., Nilsson L. G., Persson T. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology. 1996 Jan;110(1):45–51. doi: 10.1053/gast.1996.v110.pm8536887. [DOI] [PubMed] [Google Scholar]
  37. Greenberg G. R., Feagan B. G., Martin F., Sutherland L. R., Thomson A. B., Williams C. N., Nilsson L. G., Persson T. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med. 1994 Sep 29;331(13):836–841. doi: 10.1056/NEJM199409293311303. [DOI] [PubMed] [Google Scholar]
  38. Greenberger N. J., Miner P. B. Is maintenance therapy effective in Crohn's disease? Lancet. 1994 Oct 1;344(8927):900–901. doi: 10.1016/s0140-6736(94)92261-6. [DOI] [PubMed] [Google Scholar]
  39. Groux H., Bigler M., de Vries J. E., Roncarolo M. G. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med. 1996 Jul 1;184(1):19–29. doi: 10.1084/jem.184.1.19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Groux H., O'Garra A., Bigler M., Rouleau M., Antonenko S., de Vries J. E., Roncarolo M. G. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997 Oct 16;389(6652):737–742. doi: 10.1038/39614. [DOI] [PubMed] [Google Scholar]
  41. Haber C. J., Meltzer S. J., Present D. H., Korelitz B. I. Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterology. 1986 Oct;91(4):982–986. doi: 10.1016/0016-5085(86)90703-1. [DOI] [PubMed] [Google Scholar]
  42. Han J., Thompson P., Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med. 1990 Jul 1;172(1):391–394. doi: 10.1084/jem.172.1.391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Hanauer S. B. Inflammatory bowel disease. N Engl J Med. 1996 Mar 28;334(13):841–848. doi: 10.1056/NEJM199603283341307. [DOI] [PubMed] [Google Scholar]
  44. Hanauer S. B., Meyers S. Management of Crohn's disease in adults. Am J Gastroenterol. 1997 Apr;92(4):559–566. [PubMed] [Google Scholar]
  45. Hinterleitner T. A., Petritsch W., Aichbichler B., Fickert P., Ranner G., Krejs G. J. Combination of cyclosporine, azathioprine and prednisolone for perianal fistulas in Crohn's disease. Z Gastroenterol. 1997 Aug;35(8):603–608. [PubMed] [Google Scholar]
  46. Hirsch T., Susin S. A., Marzo I., Marchetti P., Zamzami N., Kroemer G. Mitochondrial permeability transition in apoptosis and necrosis. Cell Biol Toxicol. 1998 Mar;14(2):141–145. doi: 10.1023/a:1007486022411. [DOI] [PubMed] [Google Scholar]
  47. Ina K., Itoh J., Fukushima K., Kusugami K., Yamaguchi T., Kyokane K., Imada A., Binion D. G., Musso A., West G. A. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol. 1999 Jul 15;163(2):1081–1090. [PubMed] [Google Scholar]
  48. Kim N. K., Senagore A. J., Luchtefeld M. A., MacKeigan J. M., Mazier W. P., Belknap K., Chen S. H. Long-term outcome after ileocecal resection for Crohn's disease. Am Surg. 1997 Jul;63(7):627–633. [PubMed] [Google Scholar]
  49. Kreuzpaintner G., Das P. K., Stronkhorst A., Slob A. W., Strohmeyer G. Effect of intestinal resection on serum antibodies to the mycobacterial 45/48 kilodalton doublet antigen in Crohn's disease. Gut. 1995 Sep;37(3):361–366. doi: 10.1136/gut.37.3.361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Lapidus A., Bernell O., Hellers G., Löfberg R. Clinical course of colorectal Crohn's disease: a 35-year follow-up study of 507 patients. Gastroenterology. 1998 Jun;114(6):1151–1160. doi: 10.1016/s0016-5085(98)70420-2. [DOI] [PubMed] [Google Scholar]
  51. Levi M., ten Cate H., Bauer K. A., van der Poll T., Edgington T. S., Büller H. R., van Deventer S. J., Hack C. E., ten Cate J. W., Rosenberg R. D. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest. 1994 Jan;93(1):114–120. doi: 10.1172/JCI116934. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Löfberg R., Rutgeerts P., Malchow H., Lamers C., Danielsson A., Olaison G., Jewell D., Ostergaard Thomsen O., Lorenz-Meyer H., Goebell H. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut. 1996 Jul;39(1):82–86. doi: 10.1136/gut.39.1.82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Marriott J. B. TNF-alpha antagonists: monoclonal antibodies, soluble receptors, thalidomide and other novel approaches. Expert Opin Investig Drugs. 1997 Aug;6(8):1105–1108. doi: 10.1517/13543784.6.8.1105. [DOI] [PubMed] [Google Scholar]
  54. Marzo I., Brenner C., Zamzami N., Jürgensmeier J. M., Susin S. A., Vieira H. L., Prévost M. C., Xie Z., Matsuyama S., Reed J. C. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science. 1998 Sep 25;281(5385):2027–2031. doi: 10.1126/science.281.5385.2027. [DOI] [PubMed] [Google Scholar]
  55. McHugh S. M., Rowland T. L. Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation. Clin Exp Immunol. 1997 Nov;110(2):151–154. doi: 10.1111/j.1365-2249.1997.tb08310.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Monteleone G., Biancone L., Marasco R., Morrone G., Marasco O., Luzza F., Pallone F. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology. 1997 Apr;112(4):1169–1178. doi: 10.1016/s0016-5085(97)70128-8. [DOI] [PubMed] [Google Scholar]
  57. Monteleone G., Trapasso F., Parrello T., Biancone L., Stella A., Iuliano R., Luzza F., Fusco A., Pallone F. Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol. 1999 Jul 1;163(1):143–147. [PubMed] [Google Scholar]
  58. Montgomery S. M., Morris D. L., Pounder R. E., Wakefield A. J. Measles vaccination and inflammatory bowel disease. Lancet. 1997 Dec 13;350(9093):1774–1774. doi: 10.1016/s0140-6736(97)26050-2. [DOI] [PubMed] [Google Scholar]
  59. Moss M. L., Jin S. L., Becherer J. D., Bickett D. M., Burkhart W., Chen W. J., Hassler D., Leesnitzer M. T., McGeehan G., Milla M. Structural features and biochemical properties of TNF-alpha converting enzyme (TACE). J Neuroimmunol. 1997 Feb;72(2):127–129. doi: 10.1016/s0165-5728(96)00180-4. [DOI] [PubMed] [Google Scholar]
  60. Moss M. L., Jin S. L., Becherer J. D., Bickett D. M., Burkhart W., Chen W. J., Hassler D., Leesnitzer M. T., McGeehan G., Milla M. Structural features and biochemical properties of TNF-alpha converting enzyme (TACE). J Neuroimmunol. 1997 Feb;72(2):127–129. doi: 10.1016/s0165-5728(96)00180-4. [DOI] [PubMed] [Google Scholar]
  61. Muller G. W., Shire M. G., Wong L. M., Corral L. G., Patterson R. T., Chen Y., Stirling D. I. Thalidomide analogs and PDE4 inhibition. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2669–2674. doi: 10.1016/s0960-894x(98)00475-2. [DOI] [PubMed] [Google Scholar]
  62. Munkholm P. Crohn's disease--occurrence, course and prognosis. An epidemiologic cohort-study. Dan Med Bull. 1997 Jun;44(3):287–302. [PubMed] [Google Scholar]
  63. Munkholm P., Langholz E., Davidsen M., Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol. 1995 Jul;30(7):699–706. doi: 10.3109/00365529509096316. [DOI] [PubMed] [Google Scholar]
  64. Munkholm P., Langholz E., Davidsen M., Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut. 1994 Mar;35(3):360–362. doi: 10.1136/gut.35.3.360. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Neurath M. F., Becker C., Barbulescu K. Role of NF-kappaB in immune and inflammatory responses in the gut. Gut. 1998 Dec;43(6):856–860. doi: 10.1136/gut.43.6.856. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Neurath M. F., Pettersson S. Predominant role of NF-kappa B p65 in the pathogenesis of chronic intestinal inflammation. Immunobiology. 1997 Dec;198(1-3):91–98. doi: 10.1016/s0171-2985(97)80030-7. [DOI] [PubMed] [Google Scholar]
  67. Pallone F., Monteleone G. Interleukin 12 and Th1 responses in inflammatory bowel disease. Gut. 1998 Dec;43(6):735–736. doi: 10.1136/gut.43.6.735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Pearson D. C., May G. R., Fick G. H., Sutherland L. R. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995 Jul 15;123(2):132–142. doi: 10.7326/0003-4819-123-2-199507150-00009. [DOI] [PubMed] [Google Scholar]
  69. Powrie F., Coffman R. L., Correa-Oliveira R. Transfer of CD4+ T cells to C.B-17 SCID mice: a model to study Th1 and Th2 cell differentiation and regulation in vivo. Res Immunol. 1994 Jun;145(5):347–353. doi: 10.1016/s0923-2494(94)80198-3. [DOI] [PubMed] [Google Scholar]
  70. Powrie F., Mauze S., Coffman R. L. CD4+ T-cells in the regulation of inflammatory responses in the intestine. Res Immunol. 1997 Oct-Dec;148(8-9):576–581. doi: 10.1016/s0923-2494(98)80152-1. [DOI] [PubMed] [Google Scholar]
  71. Powrie F. T cells in inflammatory bowel disease: protective and pathogenic roles. Immunity. 1995 Aug;3(2):171–174. doi: 10.1016/1074-7613(95)90086-1. [DOI] [PubMed] [Google Scholar]
  72. Present D. H., Korelitz B. I., Wisch N., Glass J. L., Sachar D. B., Pasternack B. S. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980 May 1;302(18):981–987. doi: 10.1056/NEJM198005013021801. [DOI] [PubMed] [Google Scholar]
  73. Present D. H., Meltzer S. J., Krumholz M. P., Wolke A., Korelitz B. I. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989 Oct 15;111(8):641–649. doi: 10.7326/0003-4819-111-8-641. [DOI] [PubMed] [Google Scholar]
  74. Present D. H., Rutgeerts P., Targan S., Hanauer S. B., Mayer L., van Hogezand R. A., Podolsky D. K., Sands B. E., Braakman T., DeWoody K. L. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999 May 6;340(18):1398–1405. doi: 10.1056/NEJM199905063401804. [DOI] [PubMed] [Google Scholar]
  75. Russel M. G., Dorant E., Volovics A., Brummer R. J., Pop P., Muris J. W., Bos L. P., Limonard C. B., Stockbrügger R. W. High incidence of inflammatory bowel disease in The Netherlands: results of a prospective study. The South Limburg IBD Study Group. Dis Colon Rectum. 1998 Jan;41(1):33–40. doi: 10.1007/BF02236893. [DOI] [PubMed] [Google Scholar]
  76. Russel M. G., Nieman F. H., Bergers J. M., Stockbrügger R. W. Cigarette smoking and quality of life in patients with inflammatory bowel disease. South Limburg IBD Study Group. Eur J Gastroenterol Hepatol. 1996 Nov;8(11):1075–1081. doi: 10.1097/00042737-199611000-00009. [DOI] [PubMed] [Google Scholar]
  77. Russel M. G., Stockbrügger R. W. Epidemiology of inflammatory bowel disease: an update. Scand J Gastroenterol. 1996 May;31(5):417–427. doi: 10.3109/00365529609006759. [DOI] [PubMed] [Google Scholar]
  78. Russel M. G., Volovics A., Schoon E. J., van Wijlick E. H., Logan R. F., Shivananda S., Stockbrügger R. W. Inflammatory bowel disease: is there any relation between smoking status and disease presentation? European Collaborative IBD Study Group. Inflamm Bowel Dis. 1998 Aug;4(3):182–186. doi: 10.1097/00054725-199808000-00002. [DOI] [PubMed] [Google Scholar]
  79. Rutgeerts P., Goboes K., Peeters M., Hiele M., Penninckx F., Aerts R., Kerremans R., Vantrappen G. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet. 1991 Sep 28;338(8770):771–774. doi: 10.1016/0140-6736(91)90663-a. [DOI] [PubMed] [Google Scholar]
  80. Rutgeerts P., Löfberg R., Malchow H., Lamers C., Olaison G., Jewell D., Danielsson A., Goebell H., Thomsen O. O., Lorenz-Meyer H. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med. 1994 Sep 29;331(13):842–845. doi: 10.1056/NEJM199409293311304. [DOI] [PubMed] [Google Scholar]
  81. Rutgeerts P. Recurrence of Crohn's disease in the neoterminal ileum after ileal resection: is prevention therapy possible? Neth J Med. 1994 Aug;45(2):60–64. [PubMed] [Google Scholar]
  82. Stack W. A., Mann S. D., Roy A. J., Heath P., Sopwith M., Freeman J., Holmes G., Long R., Forbes A., Kamm M. A. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet. 1997 Feb 22;349(9051):521–524. doi: 10.1016/s0140-6736(97)80083-9. [DOI] [PubMed] [Google Scholar]
  83. Targan S. R., Hanauer S. B., van Deventer S. J., Mayer L., Present D. H., Braakman T., DeWoody K. L., Schaible T. F., Rutgeerts P. J. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997 Oct 9;337(15):1029–1035. doi: 10.1056/NEJM199710093371502. [DOI] [PubMed] [Google Scholar]
  84. Thompson N. P., Fleming D. M., Pounder R. E., Wakefield A. J. Crohn's disease, measles, and measles vaccination: a case-control failure. Lancet. 1996 Jan 27;347(8996):263–263. doi: 10.1016/s0140-6736(96)90438-9. [DOI] [PubMed] [Google Scholar]
  85. Thomsen O. O., Cortot A., Jewell D., Wright J. P., Winter T., Veloso F. T., Vatn M., Persson T., Pettersson E. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med. 1998 Aug 6;339(6):370–374. doi: 10.1056/NEJM199808063390603. [DOI] [PubMed] [Google Scholar]
  86. Van Deventer S. J. Tumour necrosis factor and Crohn's disease. Gut. 1997 Apr;40(4):443–448. doi: 10.1136/gut.40.4.443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Van Parijs L., Abbas A. K. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science. 1998 Apr 10;280(5361):243–248. doi: 10.1126/science.280.5361.243. [DOI] [PubMed] [Google Scholar]
  88. Van der Poll T., Lowry S. F. Epinephrine inhibits endotoxin-induced IL-1 beta production: roles of tumor necrosis factor-alpha and IL-10. Am J Physiol. 1997 Dec;273(6 Pt 2):R1885–R1890. doi: 10.1152/ajpregu.1997.273.6.R1885. [DOI] [PubMed] [Google Scholar]
  89. Watanabe M., Takaishi H., Hosoda Y., Ezaki T., Yajima T., Inoue N., Ueno Y., Iwao Y., Ishii H., Ishikawa H. CD4+ intestinal mucosal lymphocytes in the pathogenesis of Crohn's disease. J Gastroenterol. 1995 Nov;30 (Suppl 8):73–75. [PubMed] [Google Scholar]
  90. de Jong E., van Dullemen H. M., Slors J. F., Dekkers P., van Deventer S. J., Tytgat G. N. Correlation between early recurrence and reoperation after ileocolonic resection in Crohn's disease: a prospective study. J Am Coll Surg. 1996 Jun;182(6):503–508. [PubMed] [Google Scholar]
  91. van Dullemen H. M., Wolbink G. J., Wever P. C., van der Poll T., Hack C. E., Tytgat G. N., van Deventer S. J. Reduction of circulating secretory phospholipase A2 levels by anti-tumor necrosis factor chimeric monoclonal antibody in patients with severe Crohn's disease. Relation between tumor necrosis factor and secretory phospholipase A2 in healthy humans and in active Crohn's disease. Scand J Gastroenterol. 1998 Oct;33(10):1094–1098. doi: 10.1080/003655298750026813. [DOI] [PubMed] [Google Scholar]
  92. van Dullemen H. M., de Jong E., Slors F., Tytgat G. N., van Deventer S. J. Treatment of therapy-resistant perineal metastatic Crohn's disease after proctectomy using anti-tumor necrosis factor chimeric monoclonal antibody, cA2: report of two cases. Dis Colon Rectum. 1998 Jan;41(1):98–102. doi: 10.1007/BF02236903. [DOI] [PubMed] [Google Scholar]
  93. van Dullemen H. M., van Deventer S. J., Hommes D. W., Bijl H. A., Jansen J., Tytgat G. N., Woody J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995 Jul;109(1):129–135. doi: 10.1016/0016-5085(95)90277-5. [DOI] [PubMed] [Google Scholar]
  94. van der Poll T., Coyle S. M., Barbosa K., Braxton C. C., Lowry S. F. Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. J Clin Invest. 1996 Feb 1;97(3):713–719. doi: 10.1172/JCI118469. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES